Induction with oral chemotherapy (CID) followed by early autologous stem cell transplantation for de novo multiple myeloma patients
| Autor: | Arno Enno, Devinder Gill, Michael Seldon, Ralph Cobcroft, Andrew Spencer, Paula Marlton, Gavin Cull, Sandra Deveridge |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Melphalan medicine.medical_specialty Time Factors Adolescent Cyclophosphamide Administration Oral Transplantation Autologous Gastroenterology Drug Administration Schedule Autologous stem-cell transplantation Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Idarubicin Survival analysis Multiple myeloma Aged Neoplasm Staging business.industry Hematology Middle Aged medicine.disease Combined Modality Therapy Survival Analysis Surgery Transplantation Regimen Multiple Myeloma business Stem Cell Transplantation medicine.drug |
| Zdroj: | The Hematology Journal. 5:216-221 |
| ISSN: | 1476-5632 1466-4860 |
| DOI: | 10.1038/sj.thj.6200342 |
| Popis: | In an effort to minimise induction therapy-related toxicity, avoid unnecessary hospitalisation and facilitate early ASCT, we have prospectively evaluated an outpatient-based oral chemotherapeutic regimen, cyclophosphamide, idarubicin, dexamethasone (CID) in patients with previously untreated multiple myeloma (mm). Patients subsequently underwent ASCT conditioned with melphalan 200 g/m(2). A total of 36 newly diagnosed MM patients were enrolled between February 1997 and March 2000. In all 136 cycles of CID were administered requiring only four unplanned hospital admissions. Grade 3 or 4 haematological toxicities were documented following 14 cycles (10%). There were no treatment-related deaths. Response rates (PR + CR) based on an intention-to-treat basis were 66% (23 of 35, 9% CR) post-CID and 80% (28 of 35, 34% CR) post-ASCT. In all, 28 of the 35 patients remain alive with a median follow-up for surviving patients of 40 months (range, 30-67 months). Progression-free survival from the time of diagnosis was 32 months (range, 3-55+ months). Median overall survival from diagnosis has not been reached with an estimated overall survival at 4 years of 77%. CID in combination with early ASCT is an effective and well-tolerated antimyelomatous regimen and is a practical alternative to more toxic and invasive therapeutic approaches. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|